Home › Pfizer Announces Enrollment Of First Patient In Phase 3 Trial In Sickle Cell Disease
 

Keywords :   


Pfizer Announces Enrollment Of First Patient In Phase 3 Trial In Sickle Cell Disease

2015-06-24 00:50:25| Biotech - Topix.net

Pfizer Inc. today announced that the first patient has been enrolled in the RESET study - a Phase 3 clinical trial assessing the efficacy and safety of rivipansel for the treatment of vaso-occlusive crisis in hospitalized individuals with sickle cell disease who are six years of age or older. Sickle cell disease is one of the most prevalent genetic disorders in the U.S. It is a rare and debilitating chronic disease with lifelong clinical impact and reduced life expectancy; life expectancy is 48 years for females and 42 years for males with sickle cell disease.

Tags: cell trial phase disease

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.09Eastern North Pacific Tropical Weather Outlook
29.09Atlantic Tropical Weather Outlook
29.09Hurricane Isaac Graphics
29.09Hurricane Isaac Forecast Discussion Number 13
29.09Tropical Storm Joyce Graphics
29.09Hurricane Isaac Wind Speed Probabilities Number 13
29.09Hurricane Isaac Public Advisory Number 13
29.09Summary for Hurricane Isaac (AT5/AL102024)
More »